The value of remote care in the reduction of healthcare utilization in implantable cardioverter-defibrillator patients

被引:1
|
作者
van Steenbergen, Gijs [1 ]
Ben Jaddi, Oumaima [2 ]
Theuns, Dominic [2 ]
van Veghel, Dennis [1 ]
Dekker, Lukas [1 ,3 ]
Simmers, Tim [1 ]
机构
[1] Catharina Hosp, Catharina Heart Ctr, Eindhoven, Netherlands
[2] Erasmus MC, Thoraxctr, Dept Cardiol, Rotterdam, Netherlands
[3] Eindhoven Univ Technol, Dept Biomed Technol, Eindhoven, Netherlands
来源
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY | 2021年 / 44卷 / 12期
关键词
cardiac resynchronization-therapy; healthcare utilization; implantable cardioverter defibrillator; remote care; telemonitoring; HEART-FAILURE PATIENTS; FOLLOW-UP; ELECTRONIC DEVICES; EXPERT CONSENSUS; MANAGEMENT; EFFICACY;
D O I
10.1111/pace.14390
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Minimal evidence is available of the reduction in healthcare utilization of remote care in ICD patients over a longer period of follow-up. Objectives This study compared healthcare utilization up to 3 year follow-up in implantable cardioverter-defibrillator (ICD) patients with remote care compared to conventional care. Methods We conducted a retrospective cohort study of patients who received a single or dual-chamber ICD or cardiac resynchronization therapy-defibrillator (CRT-D) between 2016 and 2018. Patients with remote care and patients were compared with patients with received conventional care (control group). The primary endpoint was a composite of cardiac follow-up visits, ICD follow-up visits, telephone consultations, emergency department (ED) visits and hospital admissions and was defined as total healthcare utilization. The secondary endpoints were the individual care activities and one-year all-cause mortality. Results A total of 497 patients were included in the study, of which 299 patients were allocated to the remote care and 198 patients to the control group. Mean follow-up was 815 +/- 279 days. Remote care was associated with a significantly lower rate of adjusted total healthcare utilization in comparison to the control group that sustained for 3 subsequent follow-up years (IRR = 0.78, 95% CI [0.67 to 0.92], p < .01). One-year all-cause mortality was similar between the remote care and control group (respectively 3.0% vs. 5.5%, p = .29). Conclusions Compared to the standard follow-up of in-office care, a remote care program was associated with a sustained lower rate of planned and unplanned healthcare utilization up to 3 subsequent years after ICD/CRT-D implantation.
引用
收藏
页码:2005 / 2014
页数:10
相关论文
共 50 条
  • [31] Novel intravascular defibrillator: Defibrillation thresholds of intravascular cardioverter-defibrillator compared to conventional implantable cardioverter-defibrillator in a canine model
    Sanders, William E., Jr.
    Richey, Mark W.
    Malkin, Robert A.
    Masson, Stephen C.
    Ransbury, T. J.
    Urtz, Mark W.
    Ideker, Raymond E.
    HEART RHYTHM, 2011, 8 (02) : 288 - 292
  • [32] Subcutaneous Implantable Cardioverter-Defibrillator Technology
    Gupta, Anurag
    Al-Ahmad, Amin
    Wang, Paul J.
    HEART FAILURE CLINICS, 2011, 7 (02) : 287 - +
  • [33] Sports and Driving With an Implantable Cardioverter-Defibrillator
    Ferrick, Aileen M.
    Ferrick, Kevin J.
    CARDIOLOGY IN REVIEW, 2017, 25 (01) : 36 - 42
  • [34] Hypertrophic cardiomyopathy and the implantable cardioverter-defibrillator
    Manovel-Sanchez, Ana J.
    Pedrote-Martinez, Alonso
    Arana-Rueda, Eduardo
    de Tejada, Francisco Errazquin-Saenz
    REVISTA ESPANOLA DE CARDIOLOGIA, 2007, 60 (07): : 784 - 784
  • [35] An update on implantable cardioverter-defibrillator guidelines
    Epstein, AE
    CURRENT OPINION IN CARDIOLOGY, 2004, 19 (01) : 23 - 25
  • [36] Current status of the implantable cardioverter-defibrillator
    Gollob, MH
    Seger, JJ
    CHEST, 2001, 119 (04) : 1210 - 1221
  • [37] Racial and Ethnic Disparities in Implantable Cardioverter-Defibrillator Utilization: A Contemporary Review
    Tarryn Tertulien
    Kelvin Bush
    Larry R. Jackson
    Utibe R. Essien
    Lauren Eberly
    Current Treatment Options in Cardiovascular Medicine, 2023, 25 : 771 - 791
  • [38] Relation of multicenter automatic defibrillator implantation trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator
    Uslu, Abdulkadir
    Dogan, Cem
    Duman, Hakan
    Tanboga, Ibrahim Halil
    Askin, Lutfu
    Sevimli, Serdar
    NORTHERN CLINICS OF ISTANBUL, 2019, 6 (01) : 40 - 47
  • [39] Assessment of shoulder pain and shoulder disability in patients with implantable cardioverter-defibrillator
    Celikyurt, Umut
    Agacdiken, Aysen
    Bozyel, Serdar
    Argan, Onur
    Sade, Ilgin
    Vural, Ahmet
    Ural, Dilek
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2013, 36 (01) : 91 - 94
  • [40] Patients' Perspective on Deactivation of the Implantable Cardioverter-Defibrillator Near the End of Life
    Pedersen, Susanne S.
    Chaitsing, Rismy
    Szili-Torok, Tamas
    Jordaens, Luc
    Theuns, Dominic A. M. J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2013, 111 (10) : 1443 - 1447